Wealth Enhancement Advisory Services
CYTK icon

Wealth Enhancement Advisory Services’s Cytokinetics CYTK Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$809K Buy
9,535
+662
+7% +$47.5K ﹤0.01% 2250
2026
Q1 		$592K Sell
8,873
-1,109
-11% -$70.5K ﹤0.01% 2182
2025
Q4 		$645K Buy
9,982
+126
+1% +$7.84K ﹤0.01% 2285
2025
Q3 		$593K Buy
9,856
+1,380
+16% +$56.9K ﹤0.01% 2225
2025
Q2 		$294K Buy
8,476
+1,988
+31% +$69.1K ﹤0.01% 2660
2025
Q1 		$261K Sell
6,488
-168
-3% -$7.72K ﹤0.01% 2551
2024
Q4 		$313K Sell
6,656
-2,774
-29% -$144K ﹤0.01% 2349
2024
Q3 		$498K Sell
9,430
-1,653
-15% -$92.1K ﹤0.01% 1837
2024
Q2 		$600K Sell
11,083
-510
-4% -$30.8K ﹤0.01% 1534
2024
Q1 		$813K Buy
+11,593
New +$897K ﹤0.01% 1331

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wealth Enhancement Advisory Services's CYTK Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Cytokinetics (CYTK) stake by 7.5% in Q2 2026, buying an estimated $47.5K and bringing the position to 9,535 shares worth $809K. The position accounts for ﹤0.01% of the portfolio, ranked #2250.

Wealth Enhancement Advisory Services first reported a position in CYTK in Q1 2024 and has held it in 10 quarters since. The position peaked at $813K in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Wealth Enhancement Advisory Services held 9,535 shares of Cytokinetics worth $809K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 662 Cytokinetics shares in Q2 2026, an estimated $47.5K.
  • Cytokinetics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2250 holding.
  • Wealth Enhancement Advisory Services first reported a position in Cytokinetics in Q1 2024 and has held it in 10 quarters since.
  • Wealth Enhancement Advisory Services's Cytokinetics position peaked at $813K in Q1 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.